Effects of Renal Impairment on the Pharmacokinetics of Morinidazole: Uptake Transporter-Mediated Renal Clearance of the Conjugated Metabolites
Open Access
- 1 July 2014
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (7), 4153-4161
- https://doi.org/10.1128/aac.02414-14
Abstract
Morinidazole is a novel 5-nitroimidazole antimicrobial drug that undergoes extensive metabolism in humans via N + -glucuronidation ( N + -glucuronide of S -morinidazole [M8-1] and N + -glucuronide of R -morinidazole [M8-2]) and sulfation (sulfate conjugate of morinidazole [M7]). Our objectives were to assess the effects of renal impairment on the pharmacokinetics (PK) of morinidazole and to elucidate the potential mechanisms. In this parallel-group study, healthy subjects and patients with severe renal impairment received an intravenous infusion of 500 mg of morinidazole. Plasma and urine samples were collected and analyzed. The areas under the plasma concentration-time curves (AUC) for M7, M8-1, and M8-2 were 15.1, 20.4, and 17.4 times higher, respectively, in patients with severe renal impairment than in healthy subjects, while the AUC for morinidazole was 1.5 times higher. The urinary recovery of the major metabolites was not significantly different between the two groups over 0 to 48 h, but the renal clearances of M7, M8-1, and M8-2 in patients were 85.3%, 92.5%, and 92.2% lower, respectively. In vitro transporter studies revealed that M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 ( K m = 28.6 and 54.0 μM, respectively). Only OAT3 transported M8-1 and M8-2. Morinidazole was not a substrate for the transporter-transfected cells examined. These results revealed that the function or activity of renal uptake transporters might be impaired in patients with severe renal impairment, which accounted for dramatically increased plasma exposure and reduced renal clearance of the conjugated metabolites of morinidazole, the substrates of renal transporters in patients. It will help clinicians to adjust the dose in patients with severe renal impairment and to predict possible transporter-based drug-drug interactions.Keywords
This publication has 26 references indexed in Scilit:
- Drug transport by Organic Anion Transporters (OATs)Pharmacology & Therapeutics, 2012
- Effects of Chronic Renal Failure on Kidney Drug Transporters and Cytochrome P450 in RatsDrug Metabolism and Disposition, 2011
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of SaxagliptinClinical Pharmacokinetics, 2011
- Transporter Studies with the 3-O-Sulfate Conjugate of 17α-Ethinylestradiol: Assessment of Human Kidney Drug TransportersDrug Metabolism and Disposition, 2010
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran EtexilateClinical Pharmacokinetics, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Effects of Chronic Renal Failure on Liver Drug TransportersDrug Metabolism and Disposition, 2007
- Molecular physiology of renal organic anion transportersAmerican Journal of Physiology-Renal Physiology, 2006
- Pharmacokinetics of the Dietary Supplement CreatineClinical Pharmacokinetics, 2003
- Alteration of Drug-Protein Binding in Renal DiseaseClinical Pharmacokinetics, 1984